Cognitive Impairment Induced by Electroconvulsive Therapy. Major depressive disorder, single episode, unspecified
Conditions
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Male and female patients aged between 18 and 65 years Receiving Electroconvulsive Therapy (ECT) as diagnosed and confirmed by the treating psychiatrist.
Exclusion criteria
Exclusion criteria: A history of diagnosable neurological disorders including epilepsy, dementia, or structural brain injuries. Severe or uncontrolled systemic diseases such as cardiac, renal, or hepatic failure. Pregnancy and breastfeeding Active substance or alcohol abuse. Concurrent use of benzodiazepines. History of psychosis. Consumption of magnesium supplements or medications affecting cognitive function within the past month. History of allergy or intolerance to magnesium or its products.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of the mean total cognitive score (MoCA) before and after ECT, both within each group and between the magnesium and placebo groups. Timepoint: Before the intervention and at the end of the third month after the start of the intervention. Method of measurement: The Montreal Cognitive Assessment test. | — |
Secondary
| Measure | Time frame |
|---|---|
| Trend of changes in MoCA scores over time and across different cognitive domains, within and between groups. Timepoint: Before the intervention and at the end of the third month after the start of the intervention. Method of measurement: MoCA test.;Frequency of adverse events in the magnesium group. Timepoint: During the intervention with at least monthly monitoring. Method of measurement: Patient interview. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMahsa panahishokouh
Esfahan University of Medical Sciences
Outcome results
None listed